Innovative Anti-Nausea Smartwatch EmeTerm® Smart Set to Launch on Indiegogo
EmeTerm® Smart's story is one of heartfelt innovation. In 2010, the founder's wife experienced severe morning sickness during her pregnancy. Frustrated by the lack of effective, drug-free solutions, he was inspired to create a device that could help not only his wife but also countless others suffering from nausea. Driven by love and determination, he assembled a team of passionate and experienced professionals who shared his vision and founded WAT Medical, a Canadian medical technology company, in 2015.
Since its establishment, WAT Medical has dedicated years to developing high-precision, wearable medical devices to prevent debilitating conditions like nausea, migraines, and obesity. Co-founder,
Today, WAT Medical is proud to introduce a new smart device that exceeds expectations and transforms lives. The EmeTerm® Smart anti-nausea wristband utilizes transcutaneous electrical nerve stimulation (TENS) to provide a drug-free, side-effect-free solution for all types of nausea and vomiting. FDA-approved and boasting a success rate of up to 85%, EmeTerm® Smart effectively combats nausea in a safe and natural manner.[1]
Additionally, a study published in the British Journal of Anesthesia (BJA) confirms that wearable TENS wristbands can effectively prevent postoperative nausea and vomiting. On
The new EmeTerm® Smart model also stands out with its smart features. Users can adjust the electrical stimulation level via a touch-sensitive screen with a clear interface. Moreover, it offers timekeeping and step counting to help users better understand and improve their health. With an IP67 waterproof rating, EmeTerm® Smart can stay submerged in 1-meter-deep water for 30 minutes and is completely protected from dust, ensuring it can be used in various situations.
EmeTerm® Smart will be released via Indiegogo in
[1] Wang N, Ding P, Zheng D Y, et al. Wearable transcutaneous electrical acupoint stimulation bracelet for prevention of postoperative nausea and vomiting in patients undergoing hysteroscopic surgery: a randomised controlled trial[J]. British Journal of Anaesthesia, 2022, 129(4): e85-e87. https://www.bjanaesthesia.org.uk/article/S0007-0912(22)00348-8/fulltext |
Media Contact:
Company Name: WAT Medical
Contact: EmeTerm
Email: [email protected]
Website: EmeTerm
View original content to download multimedia:https://www.prnewswire.com/news-releases/innovative-anti-nausea-smartwatch-emeterm-smart-set-to-launch-on-indiegogo-302214305.html
SOURCE WAT Medical Enterprise Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bob's Red Mill Introduces Perfected Formula for Gluten Free 1-to-1 Baking Flour with Improved Taste and Texture
- Calibre One Announces Doug Brown as Partner
- LinkSquares Names Lyle McCutcheon-Schour SVP of Revenue to Drive Agentic CLM Growth
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share